Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside.

Article Details

Citation
Copy to clipboard

Brilland B, Garnier AS, Chevailler A, Jeannin P, Subra JF, Augusto JF

Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside.

Autoimmun Rev. 2020 Jan;19(1):102424. doi: 10.1016/j.autrev.2019.102424. Epub 2019 Nov 15.

PubMed ID
31734405 [ View in PubMed
]
Abstract

Anti-neutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitides (AAVs) are small vessel vasculitides involving predominantly ear-nose-throat, kidneys, lungs and nerves. AAVs are life-threatening diseases, especially in their most severe forms such as necrotizing crescentic glomerulonephritis (GN) and/or intra-alveolar hemorrhage. Unlike immune complex GN or anti-glomerular basement membrane GN, AAVs are classified as pauci-immune GN. However, based on recent insights from animal models, the view of AAVs as a complement-unrelated disease has been challenged. Indeed, complement activation, and especially complement alternative pathway (cAP) activation, has been shown to be determinant in AAV pathogenesis through C5a generation, a potent chemoattractant for neutrophils with priming capacities. Here, we review in vitro and in vivo data supporting the role of cAP in murine models and in human AAVs. These findings, together with the need to eradicate glucocorticoid toxicity, led to the development of an anti-C5aR molecule, CCX168, also known as avacopan. Its development and future opportunities are also discussed.

DrugBank Data that Cites this Article

Drugs